Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 16/20 | 0.61 |
| ▸ | RAF1 | P04049 | 1/20 | 0.50 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5046532 | 0.87 | P2RY1 (0.55) | P2RY1RAF1BRAF | |
| SCHEMBL5030671 | 0.86 | ABL1 (0.51) | P2RY1RAF1BRAFALDH1A1LMNA | |
| SCHEMBL5048688 | 0.86 | P2RY1 (0.55) | P2RY1RAF1BRAF | |
| SCHEMBL1307144 | 0.85 | P2RY1 (0.55) | P2RY1RAF1BRAF | |
| SCHEMBL5043220 | 0.83 | P2RY1 (0.51) | P2RY1RAF1BRAF | |
| SCHEMBL5043417 | 0.83 | P2RY1 (0.52) | P2RY1 | |
| SCHEMBL5039192 | 0.82 | CSNK1D (0.64) | P2RY1RAF1BRAF | |
| SCHEMBL5043951 | 0.82 | P2RY1 (0.54) | P2RY1KDM4E | |
| SCHEMBL5043310 | 0.82 | P2RY1 (0.51) | P2RY1 | |
| SCHEMBL5046604 | 0.81 | P2RY1 (0.54) | P2RY1RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1706398-B1 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-05-21 | — | — | EP | claimed |
| US-7470712-B2 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | claimed |
| JP-2007518809-A | — | — | 2007-07-12 | — | — | JP | claimed |
| EP-1706398-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2006-10-04 | — | — | EP | claimed |
| US-20050203146-A1 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-15 | — | — | US | claimed |
| WO-2005070920-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-04 | — | — | WO | claimed |
| EP-1706398-B1 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-05-21 | — | — | EP | disclosed |
| US-20130078728-A1 | Novel Isobaric Tandem Mass Tags for Quantitative Proteomics and Peptidomics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203146-A1 | Amino-benzazoles as P2Y1 receptor inhibitors | P2RY1, P2RY11, P2RY2 | P2RY1 1/4885RAF1 1696/4885BRAF 2474/4885 |
| US-20130078728-A1 | Novel Isobaric Tandem Mass Tags for Quantitative Proteomics and Peptidomics | SRMS, TMT1A, PTMS | P2RY1 4301/4885RAF1 1785/4885BRAF 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.